Media

News

Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

 

Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes
Bayer Inc. launches FastTRK, a complimentary clinical testing program for the diagnosis of NTRK gene fusions in TRK fusion cancer patients in Canada
Bayer announces agreements to resolve major legacy Monsanto litigation
Non-metastatic castration resistant prostate cancer treatment NUBEQA® (darolutamide) significantly improves overall survival with a favourable safety profile in men with non-metastatic prostate cancer
Bayer partners with Population Health Research Institute (PHRI) on major global research study on COVID-19 treatments
Bayer Scholarships for Students Now Accepting Applications for 2020
ALTAIR study published confirming efficacy of EYLEA® treat and extend dosing regimens for patients with wet AMD
New treatment for men with non-metastatic castration resistant prostate cancer approved in Canada